🔗 Share this article Patients Stopping Weight-Loss Injections Regain Pounds at a Quadrupled Rate Than People Using Diet and Exercise Obesity treatment involves long-term strategies. Fresh analysis reveals that patients who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who stop traditional diet and exercise regimens. Findings released in a major health publication points out that while obese people can lose about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals using these treatments must be informed of the risk of quick weight regain when the medication concludes," stated lead investigator Dr. Susan Jebb. Such speed of recovery implies a reversion to pre-treatment weight in about 18 months. Analyzing Therapies The research, which looked at 37 of studies involving thousands of patients, contrasted the results of the injectable medications with older methods. Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically have a more gradual creep back—approximately 0.1 kg a month—once they finish. The Reason for the Fast Rebound Nutrition scientists suggest the way of the jabs explains the amplified rebound. The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Long-term administration of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert. "Withdrawal of this hormone supplement results in hunger is unsuppressed, making binge eating far more likely." A Chronic Disease? Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications. Professionals say that, given the high risk of relapse, the treatment should be considered ongoing. This perspective is supported by pharmaceutical companies, who state that the results "emphasize the long-term character of obesity," similar to managing diseases like diabetes. Patient Experiences People who have come off the medication explain a intense resurgence of appetite. "I experienced a switch that goes on and I was suddenly extremely hungry," said a patient. This difficulty is compounded if individuals have not established permanent lifestyle or habit modifications during treatment. Growing Adoption Figures suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow. Adoption is more common among females compared to men. The 40s and 50s age group shows the highest usage rates. A large proportion access the drugs through private healthcare rather than the NHS. Finally, experts caution that while these medications are potent agents for weight loss, they are not a permanent fix and long-term success likely depends on integrated lifestyle changes.
Obesity treatment involves long-term strategies. Fresh analysis reveals that patients who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who stop traditional diet and exercise regimens. Findings released in a major health publication points out that while obese people can lose about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals using these treatments must be informed of the risk of quick weight regain when the medication concludes," stated lead investigator Dr. Susan Jebb. Such speed of recovery implies a reversion to pre-treatment weight in about 18 months. Analyzing Therapies The research, which looked at 37 of studies involving thousands of patients, contrasted the results of the injectable medications with older methods. Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically have a more gradual creep back—approximately 0.1 kg a month—once they finish. The Reason for the Fast Rebound Nutrition scientists suggest the way of the jabs explains the amplified rebound. The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Long-term administration of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert. "Withdrawal of this hormone supplement results in hunger is unsuppressed, making binge eating far more likely." A Chronic Disease? Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications. Professionals say that, given the high risk of relapse, the treatment should be considered ongoing. This perspective is supported by pharmaceutical companies, who state that the results "emphasize the long-term character of obesity," similar to managing diseases like diabetes. Patient Experiences People who have come off the medication explain a intense resurgence of appetite. "I experienced a switch that goes on and I was suddenly extremely hungry," said a patient. This difficulty is compounded if individuals have not established permanent lifestyle or habit modifications during treatment. Growing Adoption Figures suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow. Adoption is more common among females compared to men. The 40s and 50s age group shows the highest usage rates. A large proportion access the drugs through private healthcare rather than the NHS. Finally, experts caution that while these medications are potent agents for weight loss, they are not a permanent fix and long-term success likely depends on integrated lifestyle changes.